{"name":"Novavax","slug":"novavax","ticker":"NVAX","exchange":"NASDAQ","domain":"novavax.com","description":"Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.","hq":"Gaithersburg, MD","founded":0,"employees":"749","ceo":"John C. Jacobs","sector":"Vaccines / Protein Subunit","stockPrice":8.29,"stockChange":0.31,"stockChangePercent":3.88,"marketCap":"$1.4B","metrics":{"revenue":1123479000,"revenueGrowth":66.6,"grossMargin":63.5,"rdSpend":342320000,"netIncome":440302000,"cash":735084032,"dividendYield":0,"peRatio":3.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SARS-CoV-2 rS and Matrix-M Adjuvant patent cliff ($1.4B at risk)","drug":"SARS-CoV-2 rS and Matrix-M Adjuvant","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Novavax COVID-19 Vaccine","genericName":"Novavax COVID-19 Vaccine","slug":"novavax-covid-19-vaccine","indication":"COVID-19 prevention in adults 18 years and older","status":"phase_3"},{"name":"NVX-CoV2705 Vaccine","genericName":"NVX-CoV2705 Vaccine","slug":"nvx-cov2705-vaccine","indication":"COVID-19 prevention in adults (variant-specific formulation)","status":"phase_3"},{"name":"SARS-CoV-2 rS antigen/Matrix-M Adjuvant","genericName":"SARS-CoV-2 rS antigen/Matrix-M Adjuvant","slug":"sars-cov-2-rs-antigen-matrix-m-adjuvant","indication":"COVID-19 prevention in adults","status":"phase_3"},{"name":"SARS-CoV-2 rS/Matrix M1-Adjuvant","genericName":"SARS-CoV-2 rS/Matrix M1-Adjuvant","slug":"sars-cov-2-rs-matrix-m1-adjuvant","indication":"Prevention of COVID-19","status":"phase_3"},{"name":"CIC Vaccine with Matrix-M Adjuvant","genericName":"CIC Vaccine with Matrix-M Adjuvant","slug":"cic-vaccine-with-matrix-m-adjuvant","indication":"COVID-19 prevention","status":"phase_2"},{"name":"NVX-CoV2373 + NVX-CoV2515","genericName":"NVX-CoV2373 + NVX-CoV2515","slug":"nvx-cov2373-nvx-cov2515","indication":"COVID-19 prevention in adults (Phase 3 development)","status":"phase_3"},{"name":"NVX-CoV2373 + NVX-CoV2540","genericName":"NVX-CoV2373 + NVX-CoV2540","slug":"nvx-cov2373-nvx-cov2540","indication":"Prevention of COVID-19 in adults (Phase 3 development)","status":"phase_3"},{"name":"NVX-CoV2515","genericName":"NVX-CoV2515","slug":"nvx-cov2515","indication":"COVID-19 prevention in adults (variant-specific booster formulation)","status":"phase_3"},{"name":"NVX-CoV2540","genericName":"NVX-CoV2540","slug":"nvx-cov2540","indication":"COVID-19 prevention in adults (variant-updated formulation)","status":"phase_3"},{"name":"protein subunit: Novavax COVID-19 vaccine","genericName":"protein subunit: Novavax COVID-19 vaccine","slug":"protein-subunit-novavax-covid-19-vaccine","indication":"COVID-19 prevention in adults (primary series and booster doses)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"cTIV","genericName":"cTIV","slug":"ctiv","indication":"Seasonal influenza prevention in adults","status":"phase_3"},{"name":"ICC Vaccine","genericName":"ICC Vaccine","slug":"icc-vaccine","indication":"Other","status":"phase_1"},{"name":"Licensed seasonal influenza vaccine","genericName":"Licensed seasonal influenza vaccine","slug":"licensed-seasonal-influenza-vaccine","indication":"Prevention of seasonal influenza in adults aged 18 years and older","status":"marketed"},{"name":"NanoFlu","genericName":"NanoFlu","slug":"nanoflu","indication":"Prevention of seasonal influenza in adults","status":"phase_3"},{"name":"Pfizer mRNA COVID-19 vaccine","genericName":"Pfizer mRNA COVID-19 vaccine","slug":"pfizer-mrna-covid-19-vaccine","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"RSV F vaccine with adjuvant","genericName":"RSV F vaccine with adjuvant","slug":"rsv-f-vaccine-with-adjuvant","indication":"Prevention of respiratory syncytial virus (RSV) disease in older adults (≥60 years)","status":"phase_3"},{"name":"RSV-F Vaccine","genericName":"RSV-F Vaccine","slug":"rsv-f-vaccine","indication":"Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years)","status":"phase_3"}]}],"pipeline":[{"name":"Novavax COVID-19 Vaccine","genericName":"Novavax COVID-19 Vaccine","slug":"novavax-covid-19-vaccine","phase":"phase_3","mechanism":"Novavax COVID-19 Vaccine uses recombinant spike protein nanoparticles with a saponin-based adjuvant to stimulate immune responses against SARS-CoV-2.","indications":["COVID-19 prevention in adults 18 years and older","COVID-19 prevention in adolescents 12-17 years (in some jurisdictions)"],"catalyst":""},{"name":"NVX-CoV2705 Vaccine","genericName":"NVX-CoV2705 Vaccine","slug":"nvx-cov2705-vaccine","phase":"phase_3","mechanism":"NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants.","indications":["COVID-19 prevention in adults (variant-specific formulation)"],"catalyst":""},{"name":"SARS-CoV-2 rS antigen/Matrix-M Adjuvant","genericName":"SARS-CoV-2 rS antigen/Matrix-M Adjuvant","slug":"sars-cov-2-rs-antigen-matrix-m-adjuvant","phase":"phase_3","mechanism":"This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19.","indications":["COVID-19 prevention in adults","COVID-19 prevention in adolescents (age 12+)"],"catalyst":""},{"name":"SARS-CoV-2 rS/Matrix M1-Adjuvant","genericName":"SARS-CoV-2 rS/Matrix M1-Adjuvant","slug":"sars-cov-2-rs-matrix-m1-adjuvant","phase":"phase_3","mechanism":"SARS-CoV-2 rS/Matrix M1-Adjuvant is a vaccine that uses the SARS-CoV-2 spike protein and Matrix M1 adjuvant to stimulate an immune response against SARS-CoV-2.","indications":["Prevention of COVID-19"],"catalyst":""},{"name":"cTIV","genericName":"cTIV","slug":"ctiv","phase":"phase_3","mechanism":"cTIV is a recombinant tetravalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza virus strains.","indications":["Seasonal influenza prevention in adults"],"catalyst":""},{"name":"CIC Vaccine with Matrix-M Adjuvant","genericName":"CIC Vaccine with Matrix-M Adjuvant","slug":"cic-vaccine-with-matrix-m-adjuvant","phase":"phase_2","mechanism":"The CIC vaccine with Matrix-M adjuvant works by stimulating the body's immune system to produce a protective response against the COVID-19 virus.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"ICC Vaccine","genericName":"ICC Vaccine","slug":"icc-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Licensed seasonal influenza vaccine","genericName":"Licensed seasonal influenza vaccine","slug":"licensed-seasonal-influenza-vaccine","phase":"marketed","mechanism":"Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.","indications":["Prevention of seasonal influenza in adults aged 18 years and older"],"catalyst":""},{"name":"NVX-CoV2373 + NVX-CoV2515","genericName":"NVX-CoV2373 + NVX-CoV2515","slug":"nvx-cov2373-nvx-cov2515","phase":"phase_3","mechanism":"A bivalent recombinant protein vaccine that stimulates immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.","indications":["COVID-19 prevention in adults (Phase 3 development)"],"catalyst":""},{"name":"NVX-CoV2373 + NVX-CoV2540","genericName":"NVX-CoV2373 + NVX-CoV2540","slug":"nvx-cov2373-nvx-cov2540","phase":"phase_3","mechanism":"A bivalent recombinant protein vaccine that elicits immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.","indications":["Prevention of COVID-19 in adults (Phase 3 development)"],"catalyst":""},{"name":"NVX-CoV2515","genericName":"NVX-CoV2515","slug":"nvx-cov2515","phase":"phase_3","mechanism":"NVX-CoV2515 is a recombinant protein subunit vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19 variants.","indications":["COVID-19 prevention in adults (variant-specific booster formulation)"],"catalyst":""},{"name":"NVX-CoV2540","genericName":"NVX-CoV2540","slug":"nvx-cov2540","phase":"phase_3","mechanism":"NVX-CoV2540 is a recombinant protein vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against multiple variants of concern.","indications":["COVID-19 prevention in adults (variant-updated formulation)"],"catalyst":""},{"name":"NanoFlu","genericName":"NanoFlu","slug":"nanoflu","phase":"phase_3","mechanism":"NanoFlu is a recombinant nanoparticle-based influenza vaccine that displays hemagglutinin proteins on virus-like particles to stimulate robust immune responses.","indications":["Prevention of seasonal influenza in adults"],"catalyst":""},{"name":"Pfizer mRNA COVID-19 vaccine","genericName":"Pfizer mRNA COVID-19 vaccine","slug":"pfizer-mrna-covid-19-vaccine","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"RSV F vaccine with adjuvant","genericName":"RSV F vaccine with adjuvant","slug":"rsv-f-vaccine-with-adjuvant","phase":"phase_3","mechanism":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus (RSV) F protein, preventing RSV infection.","indications":["Prevention of respiratory syncytial virus (RSV) disease in older adults (≥60 years)","Prevention of RSV disease in infants (via maternal immunization)"],"catalyst":""},{"name":"RSV-F Vaccine","genericName":"RSV-F Vaccine","slug":"rsv-f-vaccine","phase":"phase_3","mechanism":"RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection.","indications":["Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years)","Prevention of RSV disease in infants (via maternal immunization)"],"catalyst":""},{"name":"protein subunit: Novavax COVID-19 vaccine","genericName":"protein subunit: Novavax COVID-19 vaccine","slug":"protein-subunit-novavax-covid-19-vaccine","phase":"marketed","mechanism":"The Novavax COVID-19 vaccine delivers recombinant SARS-CoV-2 spike protein nanoparticles with an adjuvant to stimulate immune responses against the virus.","indications":["COVID-19 prevention in adults (primary series and booster doses)"],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Novavax Announces FDA Approval of COVID-19 Vaccine","summary":"Novavax announced that the FDA has approved its COVID-19 vaccine for emergency use.","drugName":"SARS-CoV-2 rS and Matrix-M Adjuvant","sentiment":"positive"},{"date":"2022-12-14","type":"earnings","headline":"Novavax Reports Third Quarter 2022 Financial Results","summary":"Novavax reported its third quarter 2022 financial results, with revenue of $1.4 billion.","drugName":"","sentiment":"neutral"},{"date":"2022-08-05","type":"deal","headline":"Novavax Announces Agreement with Serum Institute of India for COVID-19 Vaccine","summary":"Novavax announced an agreement with Serum Institute of India to supply its COVID-19 vaccine.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNdmJHMURYWklDX1laVFNKYkRjNVJRU3NDSjZfaVVGSkpXaDY0U0FZVmx4a3gzdldmVlhZR3ZJdGladTd3UzFrUGpGYms3OERLREttLUp5NDNNZ3lWWE1tOXFuR1ZuVlUxeVJWM25hSFIyazZFSXhEdFhCSEJZNW40d3EzR0pvbXhtN1B5LUM1TUVUWm9fd0gzMXdKXzI?oc=5","date":"2026-02-27","type":"pipeline","source":"Seeking Alpha","summary":"Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX) - Seeking Alpha","headline":"Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQMTR4MUVxaExvaGEzWHQwbkRvNXRwUlZNS3M2TXNwZkFXVmwyVjRRSGU2dC1pcm80NEJleEVFLW9WWVZPUzdwdTU3VWc3RHRTb2V0OHEyM1VBTHRyZG1ZZWFaV2x3aGFmaEdMYWF3R0JqTkM3T2tQRWVuWWhRdWdKQTFISkgzNExXZWl4akMyelpNSGtoMWFPZnVfR05qWTFnNElxb3hPOA?oc=5","date":"2026-02-26","type":"earnings","source":"The Business Journals","summary":"Novavax’s stock soars on expected revenue jump from big pharma deals - The Business Journals","headline":"Novavax’s stock soars on expected revenue jump from big pharma deals","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQ1hpbEZhUEM4UXFzdGVtZG5vRG0xNlR6MG1xRldKemZSdEI1d2pYMXlJRElaUTh1VXZPRy1Bb1B2MEtLNU9IRUxvV1JOSklEdkpwZzBHeVV5ZTlfajU1aU9ZMjNNNmViMzJvRUp6clFBWUZpYzRNY1RGelJaWTNfcFQ4SE8xVGcxT2FvdlRSRENkaURObDF6M3loZWZqMmozTzZiOXowbDFtTEJ1WEtPVEM0cWNYWDlMaEZNc0lnYw?oc=5","date":"2026-02-23","type":"earnings","source":"TradingView","summary":"What's in Store for These 5 Medical Companies This Earnings Season? - TradingView","headline":"What's in Store for These 5 Medical Companies This Earnings Season?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOY2VVb25FQ2piZndodzRuOXRPZ3FWck56d09rdHJMalpEZEtIVlpMdXNtSzVBQ25Ra0xTeXY2akR0ZHk0cnR1N2t6V1J0ay1LZzhhOGV1WVpfZGVYVmp2aWF3NVRWem80TTd0NG5yY2VqLWdheHdjSDFmT01KTFZfcTN5OWRMWlluZmFNNlhfaVg4OElFYVFCSlRjSFBJZmp1bWRHcFRKUnlUeWxXdS1jZ2V5cnpwUQ?oc=5","date":"2026-02-13","type":"pipeline","source":"Finviz","summary":"Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know - Finviz","headline":"Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOY2t5ZHM5c2U1NTZ6T01lU04zQkxjYUp2cjZITlhyWEQ5RENOUFpYWkhOTGJFbDBTVHBmSklZcDJlVmtPT1FvVUVodm81Q3ltV0pETkNmdjlhdVBTS0xHOW10dVBkaTVaNEh5b2tDNFNJTmdtM2JXU193WVFYZ3BvWHBrVElOS29YX044RXdxeGpGZGIxUnVubUpCVlR5RzN1cFNhMk50UUZYQWdrYzdlTTNiRkNDYkY1X2pNa2hzNEVQWk01ZTVJclBURFJwZDBKbURWZHRtckdQQQ?oc=5","date":"2026-01-31","type":"pipeline","source":"The Globe and Mail","summary":"Novavax (NVAX) Gets a Sell from Bank of America Securities - The Globe and Mail","headline":"Novavax (NVAX) Gets a Sell from Bank of America Securities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPOExJSU9HVkZ3ejhGZDh1Y0FGMDdYNVkwdDM5THdtd0VpNHNCY0hIN1ZiSldsa3VVRWJkOUVpT2F4T3pNNk9fR2dZaFhJVWFrY3BKXzVoc0dNSVYtcjRxUzBhZlQwTVhZaEVGd3lJMVptWXFkZEczUlhQTnJNeEVTQmN5dlBYMXJUdDh3alhYbFc?oc=5","date":"2026-01-21","type":"deal","source":"The Pharma Letter","summary":"Novavax inks license agreement with Pfizer - The Pharma Letter","headline":"Novavax inks license agreement with Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPeVBTMUtsSGxTOTVGQnZlak80RnBRSnBiTk1VLWFmcl9hQkpyd0hVLTZjOW5RcWVaYUJ3NDMwY2lWS3JSNFcxZlc5aklMS3RyMWMtTHl3WkJmZ1hkVkFZVENpX1ctZWNJaVU2bjJpclV6YUdueVVGR3liVl9GeEFvWjZCN3h0R3FaLVpZZHMwSVQ5NHNSOGZ3?oc=5","date":"2026-01-21","type":"deal","source":"Finviz","summary":"Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz","headline":"Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQbE5pTzFnaDVLSTVQZDVlV2hQVFBZUjB3RUxMNHczc3BKMjdKNjNLeTdpSXZsbDhmQmR3dUdycl9MTGpGRDFyZlgwOE1jMjBSTjF0Y3dlMjdFNjV0NktKVjV3YXA0WHROa1poaGpfcjVHRnlzQzFpVmF3Y3pQRVFtYkdHdmc4aGNGaEk3OGxBOVcxelp3a3g1NHZOSWhhb0ZMUXo2VElfUTNzbm00?oc=5","date":"2026-01-20","type":"deal","source":"The Business Journals","summary":"Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M - The Business Journals","headline":"Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOdVJKdXBGdjlHU1h1LU1PTlpQRWNJeU9TMnBYa0pKeVBzaUhyNVEtOFI3cjlaN3pWbk9TWWtTOGRwMXVpUjFsbTdsM2dmcmlzVFF5UFJpeXJyVE05U1ZzQ2E2UFZpdnVUZW9hMHZxbjNILUx6eGdORlVnZUltR3BvWTM2bGJiVmtSNGVwT2d1UGZhVFVoLWdHS082TTd4ZVRKMU04Zm56aw?oc=5","date":"2026-01-03","type":"pipeline","source":"TechStock²","summary":"Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot - TechStock²","headline":"Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNbk1STXlkOUZ5Mko1SVVlT1Z3UFB4RUlZYmhoY2phbjd4RWI0R1J1Q0VkWXdzNjRyeHoyMndZbHhWbXdjbWFhcDZSLXdoekNqemVWdV9xVnhkSUYxZmttOURiWTNxVDBBa0hCRVgzNmVVdHF5YUducE5xS3JfRDQtS3NMYlQ4Z1VOTXNhVnpwa1R6MkZMalpVZDJZVWo3N0dwRVRmTHpvVlowdlhnVEJSbXA2dXJOVzZuSHdjXzlEWEtmVU1Va3VuMW9ZTDRoZFVWYjhxOGFwMHlvT20tenE3bURlbF95Vk0?oc=5","date":"2025-10-14","type":"pipeline","source":"Reuters","summary":"Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps - Reuters","headline":"Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQYUhNR0trcnB0OFpEbUdKbEt2NGNFNVdtTENKNXpPUjFtbF9faGUyNFItZHBLR294Y1hRcGdiTVU1cjlUaGRTLVJpbV9HRENqLW1oSFlCUS15Z3R3NjVoejQyYVB5UHdrZkpUaEthWDZRaFZHSURKQ2trMGxneHJ1YmxQOFhTRFU5NFBtUWJHc2t1OUQxZl9xRVh4VGd3aVFhRy1MNlRJaV9VaVprVGVRazFvLTVKNFFhU19KSS12VlV2T0RUcTlSclR4NVM3NG5pSWhmWGFR?oc=5","date":"2025-10-14","type":"pipeline","source":"Stocktwits","summary":"Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity - Stocktwits","headline":"Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQVVk5eXJEa2dPcXBBS3ltVHMwbEFZOVJoMkhZODJZaVJvVmktWWdHV3J2V3MwWENGbEE2VVE5WFBUMy1hejJQS3hRMl8zRnYwY1dLMklsM19Vc0xpZTl3d1BoTjJHOWZFelFmWVNsekFrb0hQSjAwNVljWW1QUnM3UUFDU2w1MFU?oc=5","date":"2025-05-22","type":"regulatory","source":"Yahoo Finance","summary":"Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - Yahoo Finance","headline":"Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More","sentiment":"positive"}],"patents":[{"drugName":"SARS-CoV-2 rS and Matrix-M Adjuvant","drugSlug":"covid-19-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":17,"phaseCounts":{"phase_3":12,"phase_2":1,"phase_1":1,"marketed":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Moderna Therapeutics","BioNTech"],"therapeuticFocus":["Infectious diseases","Vaccines"],"financials":{"source":"sec_edgar","revenue":1123479000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1123479000,"period":"2025-12-31"},{"value":682162000,"period":"2024-12-31"},{"value":682162000,"period":"2024-12-31"},{"value":983705000,"period":"2023-12-31"},{"value":983705000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":342320000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":440302000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1176512000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.29,"previousClose":7.98,"fiftyTwoWeekHigh":11.97,"fiftyTwoWeekLow":5.01,"fiftyTwoWeekRange":"5.01 - 11.97","fiftyDayAverage":9.29,"twoHundredDayAverage":8.04,"beta":2.65,"enterpriseValue":843192832,"forwardPE":-10.7,"priceToBook":-10.55,"priceToSales":1.2,"enterpriseToRevenue":0.75,"enterpriseToEbitda":1.43,"pegRatio":0,"ebitda":590852992,"ebitdaMargin":52.6,"freeCashflow":-331942880,"operatingCashflow":-244635008,"totalDebt":278048000,"debtToEquity":0,"currentRatio":2.13,"returnOnAssets":25.7,"returnOnEquity":0,"analystRating":"2.3 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":13.78,"targetHighPrice":25,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5,"institutionHeldPercent":70.1,"sharesOutstanding":162935945,"floatShares":140468708,"sharesShort":48625229,"shortRatio":10.07,"shortPercentOfFloat":29.8,"epsTrailing":2.58,"epsForward":-0.77,"revenuePerShare":6.93,"bookValue":-0.79,"officers":[{"age":58,"name":"Mr. John Charles Jacobs M.B.A.","title":"President, CEO & Director"},{"age":59,"name":"Mr. James Patrick Kelly C.F.A.","title":"Executive VP, CFO & Treasurer"},{"age":62,"name":"Mr. Mark J. Casey Esq.","title":"Executive VP, Chief Legal Officer & Corporate Secretary"},{"age":57,"name":"Ms. Elaine  O'Hara","title":"Executive VP & Chief Strategy Officer"},{"age":68,"name":"Mr. Richard P. Crowley","title":"Executive VP & COO"},{"age":null,"name":"Luis  Sanay C.F.A.","title":"Vice President of Investor Relations"},{"age":54,"name":"Mr. Troy  Morgan Esq., J.D.","title":"Senior VP, Deputy General Counsel & Chief Compliance Officer"},{"age":null,"name":"Ms. Erika S. Trahan","title":"Associate Director of Investor & Public Relations"}],"industry":"Biotechnology","irWebsite":"http://www.novavax.com/go.cfm?do=Stock.GetQuote","website":"https://www.novavax.com","phone":"240 268 2000"}}